264 related articles for article (PubMed ID: 15313023)
1. Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 Oct; 154(2):353-63. PubMed ID: 15313023
[TBL] [Abstract][Full Text] [Related]
2. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
[TBL] [Abstract][Full Text] [Related]
3. The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?
Srinivasan J; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jun; 369(6):629-38. PubMed ID: 15118809
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Srinivasan J; Schmidt WJ
Eur J Neurosci; 2003 Jun; 17(12):2586-92. PubMed ID: 12823465
[TBL] [Abstract][Full Text] [Related]
5. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
Alam M; Danysz W; Schmidt WJ; Dekundy A
Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571
[TBL] [Abstract][Full Text] [Related]
6. Intensification of cataleptic response in 6-hydroxydopamine-induced neurodegeneration of substantia nigra is not dependent on the degree of dopamine depletion.
Srinivasan J; Schmidt WJ
Synapse; 2004 Mar; 51(3):213-8. PubMed ID: 14666519
[TBL] [Abstract][Full Text] [Related]
7. Functional recovery of locus coeruleus noradrenergic neurons after DSP-4 lesion: effects on dopamine levels and neuroleptic induced-parkinsonian symptoms in rats.
Srinivasan J; Schmidt WJ
J Neural Transm (Vienna); 2004 Jan; 111(1):13-26. PubMed ID: 14714212
[TBL] [Abstract][Full Text] [Related]
8. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
Alam M; Mayerhofer A; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the alpha2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats.
Srinivasan J; Schmidt WJ
J Neural Transm (Vienna); 2005 Sep; 112(9):1223-36. PubMed ID: 15614426
[TBL] [Abstract][Full Text] [Related]
10. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
Ahmad M; Saleem S; Ahmad AS; Yousuf S; Ansari MA; Khan MB; Ishrat T; Chaturvedi RK; Agrawal AK; Islam F
J Neurochem; 2005 Apr; 93(1):94-104. PubMed ID: 15773909
[TBL] [Abstract][Full Text] [Related]
11. The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Buck K; Ferger B
Synapse; 2010 Feb; 64(2):117-26. PubMed ID: 19771592
[TBL] [Abstract][Full Text] [Related]
12. Noradrenergic lesion of the locus coeruleus increases the firing activity of the medial prefrontal cortex pyramidal neurons and the role of alpha2-adrenoceptors in normal and medial forebrain bundle lesioned rats.
Wang Y; Zhang QJ; Liu J; Ali U; Gui ZH; Hui YP; Wang T; Chen L; Li Q
Brain Res; 2010 Apr; 1324():64-74. PubMed ID: 20153300
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus.
Guiard BP; El Mansari M; Blier P
Mol Pharmacol; 2008 Nov; 74(5):1463-75. PubMed ID: 18703671
[TBL] [Abstract][Full Text] [Related]
15. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
16. The alpha 2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms.
Invernizzi RW; Garavaglia C; Samanin R
Neuropsychopharmacology; 2003 May; 28(5):872-9. PubMed ID: 12644843
[TBL] [Abstract][Full Text] [Related]
17. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex.
Devoto P; Flore G; Pani L; Gessa GL
Mol Psychiatry; 2001 Nov; 6(6):657-64. PubMed ID: 11673793
[TBL] [Abstract][Full Text] [Related]
18. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
Sindhu KM; Saravanan KS; Mohanakumar KP
Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
[TBL] [Abstract][Full Text] [Related]
19. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
